{
    "id": 32721,
    "fullName": "FHL2 - GLI2",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FHL2-GLI2 results from the fusion of FHL2 and GLI2 (PMID: 31896750), which leads to increased cell proliferation, migration, and colony formation, and elevated expression of calreticulin, Foxl2, and Shh pathway genes (PMID: 31896750). FHL2-GLI2 has been identified in ovarian sclerosing stromal tumors (PMID: 31896750).",
            "references": [
                {
                    "id": 18063,
                    "pubMedId": 31896750,
                    "title": "Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31896750"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2274,
        "geneSymbol": "FHL2",
        "terms": [
            "FHL2",
            "AAG11",
            "DRAL",
            "FHL-2",
            "SLIM-3",
            "SLIM3"
        ]
    },
    "variant": "FHL2 - GLI2",
    "createDate": "03/09/2020",
    "updateDate": "03/09/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2736,
                "geneSymbol": "GLI2",
                "terms": [
                    "GLI2",
                    "CJS",
                    "HPE9",
                    "PHS2",
                    "THP1",
                    "THP2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 20928,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erivedge (vismodegib) inhibited growth, migration, and colony formation of a human basal cell carcinoma cell line expressing an FHL2-GLI2 fusion in culture (PMID: 31896750).",
            "molecularProfile": {
                "id": 35351,
                "profileName": "FHL2 - GLI2"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18063,
                    "pubMedId": 31896750,
                    "title": "Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31896750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20931,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited growth of a human cell line expressing an FHL2-GLI2 fusion in culture (PMID: 31896750).",
            "molecularProfile": {
                "id": 35351,
                "profileName": "FHL2 - GLI2"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18063,
                    "pubMedId": 31896750,
                    "title": "Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31896750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20930,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited growth of a human medulloblastoma cell line expressing an FHL2-GLI2 fusion in culture (PMID: 31896750).",
            "molecularProfile": {
                "id": 35351,
                "profileName": "FHL2 - GLI2"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18063,
                    "pubMedId": 31896750,
                    "title": "Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31896750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20932,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited growth of a human basal cell carcinoma cell line expressing an FHL2-GLI2 fusion in culture (PMID: 31896750).",
            "molecularProfile": {
                "id": 35351,
                "profileName": "FHL2 - GLI2"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18063,
                    "pubMedId": 31896750,
                    "title": "Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31896750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20929,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erivedge (vismodegib) inhibited growth, migration, and colony formation of a human medulloblastoma cell line expressing an FHL2-GLI2 fusion in culture (PMID: 31896750).",
            "molecularProfile": {
                "id": 35351,
                "profileName": "FHL2 - GLI2"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 50902,
                "name": "medulloblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18063,
                    "pubMedId": 31896750,
                    "title": "Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31896750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erivedge (vismodegib) inhibited growth of a human cell line expressing an FHL2-GLI2 fusion in culture (PMID: 31896750).",
            "molecularProfile": {
                "id": 35351,
                "profileName": "FHL2 - GLI2"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18063,
                    "pubMedId": 31896750,
                    "title": "Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31896750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35351,
            "profileName": "FHL2 - GLI2",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}